Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

The relation of plasma cholinesterases to response to clinical doses of succinylcholine.

Kalow W.

Can J Anaesth. 2008 Dec;55(12):860-68. doi: 10.1007/BF03034058. No abstract available.

PMID:
19050090
2.

Personalized medicine: some thoughts.

Kalow W.

Mcgill J Med. 2007 Jan;10(1):58. No abstract available.

3.

CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.

Aklillu E, Kalow W, Endrenyi L, Harper P, Miura J, Ozdemir V.

Pharmacogenet Genomics. 2007 Nov;17(11):989-93.

PMID:
18075468
4.

CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited.

Ozdemir V, Bertilsson L, Miura J, Carpenter E, Reist C, Harper P, Widén J, Svensson JO, Albers LJ, Kennedy JL, Endrenyi L, Kalow W.

Pharmacogenet Genomics. 2007 May;17(5):339-47.

PMID:
17429316
5.
6.

Pharmacogenomics: historical perspective and current status.

Kalow W.

Methods Mol Biol. 2005;311:3-15. Review.

PMID:
16100395
7.

A pharmacogeneticist's look at drug effects and the drug development process: an overview.

Kalow W.

Expert Opin Pharmacother. 2005 Jul;6(8):1299-303. Review.

PMID:
16013980
8.

A simple test for acetylator phenotype using caffeine. 1984.

Grant DM, Tang BK, Kalow W.

Br J Clin Pharmacol. 2004 Dec;58(7):S788-93; discussion S794-5. No abstract available.

9.

Human pharmacogenomics: the development of a science.

Kalow W.

Hum Genomics. 2004 Aug;1(5):375-80.

10.

Atypical plasma cholinesterase. A personal discovery story: a tale of three cities.

Kalow W.

Can J Anaesth. 2004 Mar;51(3):206-11. No abstract available.

PMID:
15010399
11.

Pharmacogenetics and personalised medicine.

Kalow W.

Fundam Clin Pharmacol. 2002 Oct;16(5):337-42. Review.

PMID:
12602458
12.

Medical practice, race, and drug use.

Kalow W.

Clin Pharmacol Ther. 2003 Jan;73(1):132-4. No abstract available.

PMID:
12545152
13.

Mulitvariate cluster analysis of a human hepatic cytochrome P450 database.

Sy SK, Johnston JA, Class CF, Roberts EA, Kalow W, Tang BK.

Eur J Clin Pharmacol. 2002 Nov;58(8):559-62. No abstract available.

PMID:
12536990
14.

Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression.

Sy SK, Ciaccia A, Li W, Roberts EA, Okey A, Kalow W, Tang BK.

Eur J Clin Pharmacol. 2002 Aug;58(5):357-65. Epub 2002 Jul 13.

PMID:
12185560
15.

Both populations and individuals are evolutionary targets: pharmacogenomic and cultural indicators.

Kalow W.

Pharmacogenomics J. 2002;2(1):12-4. No abstract available.

PMID:
11990373
16.

Multigenic traits and risk assessment in pharmacology: a population approach.

Kalow W, Ozdemir V, Tothfalusi L.

Pharmacogenomics J. 2001;1(4):234-6. No abstract available.

PMID:
11908764
17.

Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine.

Ozdemir V, Kalow W, Okey AB, Lam MS, Albers LJ, Reist C, Fourie J, Posner P, Collins EJ, Roy R.

J Clin Psychopharmacol. 2001 Dec;21(6):603-7.

PMID:
11763009
18.
19.

CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.

Ozdemir V, Kalow W, Posner P, Collins EJ, Kennedy JL, Tang BK, Albers LJ, Reist C, Roy R, Walkes W, Afra P.

J Clin Psychopharmacol. 2001 Aug;21(4):398-407.

PMID:
11476124
20.

Pharmacogenetics, pharmacogenomics, and pharmacobiology.

Kalow W.

Clin Pharmacol Ther. 2001 Jul;70(1):1-4. Review. No abstract available.

PMID:
11452237
21.

Pharmacogenetics in perspective.

Kalow W.

Drug Metab Dispos. 2001 Apr;29(4 Pt 2):468-70. No abstract available.

22.

What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?

Ozdemir V, Shear NH, Kalow W.

Drug Saf. 2001;24(2):75-85. Review.

PMID:
11235820
23.

Perspectives in pharmacogenetics.

Kalow W.

Arch Pathol Lab Med. 2001 Jan;125(1):77-80.

PMID:
11151057
24.

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.

Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD.

Pharmacogenetics. 2000 Jul;10(5):373-88.

PMID:
10898107
25.

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, Potkin SG, Alva G, Kalow W, Macciardi FM, Kennedy JL.

Mol Psychiatry. 2000 Jul;5(4):410-7.

PMID:
10889552
26.

The science of pharmacological variability: an essay.

Kalow W, Ozdemir V, Tang BK, Tothfalusi L, Endrenyi L.

Clin Pharmacol Ther. 1999 Nov;66(5):445-7. No abstract available.

PMID:
10579470
27.

Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers.

Ozdemir V, Tyndale RF, Reed K, Herrmann N, Sellers EM, Kalow W, Naranjo CA.

J Clin Psychopharmacol. 1999 Oct;19(5):472-5. No abstract available.

PMID:
10505591
28.

Repeat administration of drugs as a means to assess the genetic component in pharmacological variability.

Kalow W, Endrenyi L, Tang B.

Pharmacology. 1999 Jun;58(6):281-4. Review. No abstract available.

PMID:
10325572
29.

Pharmacogenetic research: a revolutionary science.

Kalow W.

J Psychiatry Neurosci. 1999 Mar;24(2):139-40. No abstract available.

30.

Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research.

Kalow W, Tang BK, Endrenyi L.

Pharmacogenetics. 1998 Aug;8(4):283-9. Review.

PMID:
9731714
31.

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, Cola P, Howard A, Badri F, Nöthen MM, Kalow W, Kennedy JL.

Neuropsychopharmacology. 1998 Aug;19(2):123-32.

32.

Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.

Ozdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Reed K, Kalow W.

J Clin Psychopharmacol. 1998 Jun;18(3):198-207.

PMID:
9617978
33.

The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline.

Ozdemir V, Naranjo CA, Herrmann N, Shulman RW, Sellers EM, Reed K, Kalow W.

J Clin Psychopharmacol. 1998 Feb;18(1):55-61.

PMID:
9472843
34.

Pharmacogenetics in biological perspective.

Kalow W.

Pharmacol Rev. 1997 Dec;49(4):369-79. Review.

35.

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.

Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W.

Clin Pharmacol Ther. 1997 Sep;62(3):334-47.

PMID:
9333110
36.

Interactions of amphetamine analogs with human liver CYP2D6.

Wu D, Otton SV, Inaba T, Kalow W, Sellers EM.

Biochem Pharmacol. 1997 Jun 1;53(11):1605-12.

PMID:
9264312
37.

Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole.

Pastrakuljic A, Tang BK, Roberts EA, Kalow W.

Biochem Pharmacol. 1997 Feb 21;53(4):531-8.

PMID:
9105404
38.
40.

A sensitive method for determination of cytochrome P4502D6 activity in vitro using bupranolol as substrate.

Appanna G, Tang BK, Mller R, Kalow W.

Drug Metab Dispos. 1996 Mar;24(3):303-6.

PMID:
8820420
41.

Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans.

Tang BK, Kalow W.

Methods Enzymol. 1996;272:124-31. No abstract available.

PMID:
8791769
42.

Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam.

Patel M, Tang BK, Grant DM, Kalow W.

Pharmacogenetics. 1995 Oct;5(5):287-97.

PMID:
8563769
43.

Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat.

Wu D, Otton SV, Kalow W, Sellers EM.

J Pharmacol Exp Ther. 1995 Sep;274(3):1431-7.

PMID:
7562518
44.

Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.

Schadel M, Wu D, Otton SV, Kalow W, Sellers EM.

J Clin Psychopharmacol. 1995 Aug;15(4):263-9.

PMID:
7593709
45.

Life of a pharmacologist or the rich life of a poor metabolizer.

Kalow W.

Pharmacol Toxicol. 1995 Apr;76(4):221-7. No abstract available.

PMID:
7617550
46.

(S)oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7.

Patel M, Tang BK, Kalow W.

Pharmacogenetics. 1995 Feb;5(1):43-9.

PMID:
7773302
47.

Induction of P-450 in workers exposed to dioxin.

Halperin W, Kalow W, Sweeney MH, Tang BK, Fingerhut M, Timpkins B, Wille K.

Occup Environ Med. 1995 Feb;52(2):86-91.

48.

Low CYP1A2 activity in rural Shona children of Zimbabwe.

Masimirembwa CM, Beke M, Hasler JA, Tang BK, Kalow W.

Clin Pharmacol Ther. 1995 Jan;57(1):25-31.

PMID:
7828378
49.

Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. 4.

Tang BK, Kalow W.

Eur J Clin Pharmacol. 1995;47(5):449-51.

PMID:
7720768
50.

Caffeine biotransformation in human hepatocyte lines derived from normal liver tissue.

Roberts EA, Furuya KN, Tang BK, Kalow W.

Biochem Biophys Res Commun. 1994 Jun 15;201(2):559-66.

PMID:
8002987

Supplemental Content

Support Center